Thus, these findings were congruent with our working hypothesis that diabetes-induced LEAD can cause femoral artery injuries associated with the upregulation of vascular AEGs, ET-1, iNOS, inflammation, as well as dyslipidemia that can importantly be ameliorated by the anti-hyperglycemic drug, metformin. The gene discussed is NOS2; the disease is metabolic syndrome.